No fat chicks; we have enough of our own
- Thread starter Diogenes
- Start date
T. A. Gardner
Serial Thread Killer
Good. Back in the Ellis Island days anyone with some sort of serious health condition would be isolated then deported back to where they came from. The US wasn't letting in the sickly or medically costly even then.
The reason Cowboys drive lifted trucks. Fat chicks can't jump.
T. A. Gardner
Serial Thread Killer
Maybe POTUs doesn't want Medicare scammed.
On November 6, 2025—just days ago—when President Trump announced a landmark deal with manufacturers Novo Nordisk and Eli Lilly to expand Medicare (and Medicaid) coverage for GLP-1 drugs like Wegovy and Zepbound (tirzepatide) explicitly for weight management, bypassing the long-standing ban. This reverses earlier Trump administration hesitance; in April 2025, they rejected a Biden-era proposal to cover obesity drugs due to projected $35 billion in costs over a decade.Key details of the deal:
On November 6, 2025—just days ago—when President Trump announced a landmark deal with manufacturers Novo Nordisk and Eli Lilly to expand Medicare (and Medicaid) coverage for GLP-1 drugs like Wegovy and Zepbound (tirzepatide) explicitly for weight management, bypassing the long-standing ban. This reverses earlier Trump administration hesitance; in April 2025, they rejected a Biden-era proposal to cover obesity drugs due to projected $35 billion in costs over a decade.Key details of the deal:
- Negotiated Pricing: Drugmakers agreed to supply Wegovy (and similar drugs) to Medicare at $245 per monthly dose—about 80% below list price—enabling a flat $50 copay for qualifying enrollees.
- Eligibility Criteria: Broader than just heart disease—now includes:
- BMI ≥35 (severe obesity).
- BMI ≥27 with prediabetes.
- BMI ≥30 with advanced kidney disease, heart failure, or uncontrolled hypertension.This could newly qualify ~10% of Medicare enrollees (millions more), per administration estimates.
- Timeline: Coverage starts via a pilot program in mid-2026, with full rollout by July 2026. A new "TrumpRx" direct-to-consumer website will launch in 2026 for discounted purchases.
- Rationale: Trump framed it as fulfilling campaign promises to lower drug costs and improve health outcomes, noting polls show strong public support. It also ties into ongoing Inflation Reduction Act negotiations, where semaglutide prices could drop further by 2027.
Depends on how much it is rated for.You need one of these for the fat chics
T. A. Gardner
Serial Thread Killer
That one's good to a half ton. For the really big whales, you needDepends on how much it is rated for.
